Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-083
- Development stage
- Unknown
- Lead developer
- Neusignal Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NTX-083 is an investigational **small-molecule** therapeutic being developed by Neusignal Therapeutics for **Alzheimer's disease**. Public disclosures describe it as a **K-ATP channel inhibitor**, and third-party drug intelligence sources also describe it as an **ATP1A3 inhibitor**. The program has entered **Phase 1** development: an investigator-initiated first-in-human single-dose study in healthy volunteers at the University of Tokyo Hospital evaluated safety, tolerability, and pharmacokinetics, and a company-sponsored multiple ascending dose Phase 1 study in healthy subjects was subsequently registered. Neusignal has also indicated plans to use these data to support a future Phase 1b study in patients with Alzheimer's disease in the United States.
02
Targets
KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on NTX-083.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-083.